Overview

Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)

Status:
Completed

Trial end date:
2008-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the effectiveness, safety, and tolerability of MK7009 in patients infected with Hepatitis C

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.